Corrigendum: Metastatic extramammary Paget's disease: Pathogenesis and novel therapeutic approach [Front Oncol, 8, (2018), (38)] doi: 10.3389/fonc.2018.00038

Research output: Contribution to journalComment/debate

Abstract

In the published article, there was an error in the number of ongoing clinical trial for HER2-positive unresectable or metastatic EMPD "(UMIN-000006629)". Instead of "(UMIN-000006629)", it should be "(UMIN000021311)". The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Original languageEnglish
Article number47
JournalFrontiers in Oncology
Volume8
Issue numberMAR
DOIs
Publication statusPublished - 2018 Mar 12

Keywords

  • Anti-PD-1 antibody
  • CD163+M2 macrophage
  • CXCR4-stromal cell-derived factor-1 axis
  • HER2-PI3K/ERK signaling
  • Lymphangiogenesis
  • Metastatic extramammary Paget's disease
  • Mismatch-repair deficient
  • Receptor activator of nuclear factor kappa-B ligand-RANK signaling

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Corrigendum: Metastatic extramammary Paget's disease: Pathogenesis and novel therapeutic approach [Front Oncol, 8, (2018), (38)] doi: 10.3389/fonc.2018.00038'. Together they form a unique fingerprint.

  • Cite this